Celecoxib, Ibuprofen and the Antiplatelet Effect of Aspirin

Exclusion Criteria

• •1. active gastrointestinal disease (e.g. Crohn's disease or ulcerative colitis) or any evidence of concomitant disease which may lead to early termination of the study;
• •2. history of active peptic ulceration, gastrointestinal bleeding, esophageal, gastric or duodenal ulcer;
• •3. known hypersensitivity to COX-2 inhibitors, analgesics, antipyretics, sulfonamides or NSAIDs;
• •4. treatment with any investigational drug within the previous 30 days;
• •5. previous participation in this study;
• •6. evidence of neoplasm or any other severe disease of any organ, including any psychiatric illness;
• •7. clinically relevant deviations from the normal range in laboratory tests;
• •8. recent history or suspicion of alcohol abuse or drug addiction;
• •9. subjects unlikely to be collaborative or to give reliable answers;
• •10. pregnancy or lactation; female or childbearing potential without a clinical accepted contraceptive method;
• •11. any severe pathology that can interfere with the treatment or the clinical or instrumental tests of the trial;
• •12. intake of antiaggregant, anticoagulant, diuretic, beta-blocker, ACE- inhibitor, lithium, methotrexate, cimetidine, digoxin;
• •13. contraindications to NSAIDs.